|
US2018256534A1
|
|
Ketamine and cytochrome p 450 inhibitor combinations
|
|
US2017354636A1
|
|
Methods for inhibiting tumors and drug resistance
|
|
AU2015200721A1
|
|
Compositions and methods for inhibiting cytochrome P450 2D6
|
|
EP2254410A1
|
|
Methods for inhibiting drug degradation
|
|
CA2716514A1
|
|
Hiv protease inhibitor and cytochrome p450 inhibitor combinations
|
|
EP2257160A1
|
|
Diamide inhibitors of cytochrome p450
|
|
CA2716347A1
|
|
Amino acid inhibitors of cytochrome p450
|
|
WO2009070744A1
|
|
Compositions and methods for inhibiting cytochrome p450 2d6
|
|
CN101674822A
|
|
compositions and methods for inhibiting cytochrome p450
|
|
EP2422781A1
|
|
Resistance-repellent retroviral protease inhibitors
|
|
AU2005222435A1
|
|
Resistance-repellent retroviral protease inhibitors
|
|
CN101080237A
|
|
Antiviral agents for the treatment, control and prevention of infections by coronaviruses
|
|
AU2004277370A1
|
|
Antiviral agents for the treatment, control and prevention of infections by coronaviruses
|
|
NZ567952A
|
|
Long acting biologically active conjugates
|
